{"filing":{"accession_number":"0001674930-26-000025","cik":"0001674930","ticker":"FLGT","company_name":"Fulgent Genetics, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"flgt-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1674930/000167493026000025/flgt-20260521.htm"},"events":[{"id":9592,"run_id":8414,"accession_number":"0001674930-26-000025","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces release of interim Phase 2 clinical trial data for FID-007 in combination with cetuximab for head and neck squamous cell carcinoma. While clinical trial results can be material to biotech/pharma investors, this filing lacks specificity about the trial outcomes, efficacy metrics, or clinical significance—it merely announces that an abstract was \"released\" without disclosing the actual results. This appears to be a clinical milestone announcement rather than a traditional earnings release or material event with clear financial/operational impact, warranting classification as other_material.","company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1256,"accession_number":"0001674930-26-000025","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces release of interim Phase 2 clinical trial data for FID-007 in combination with cetuximab for head and neck squamous cell carcinoma. While clinical trial results can be material to biotech/pharma investors, this filing lacks specificity about the trial outcomes, efficacy metrics, or clinical significance—it merely announces that an abstract was \"released\" without disclosing the actual results. This appears to be a clinical milestone announcement rather than a traditional earnings release or material event with clear financial/operational impact, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:21:31.675742+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1256,"accession_number":"0001674930-26-000025","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces release of interim Phase 2 clinical trial data for FID-007 in combination with cetuximab for head and neck squamous cell carcinoma. While clinical trial results can be material to biotech/pharma investors, this filing lacks specificity about the trial outcomes, efficacy metrics, or clinical significance—it merely announces that an abstract was \"released\" without disclosing the actual results. This appears to be a clinical milestone announcement rather than a traditional earnings release or material event with clear financial/operational impact, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:21:31.675742+00:00","company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","filing_date":"2026-05-21"}]}